Novartis is constructing a $46,000-square-foot radioligand therapy manufacturing site in Texas—a strategic move in its $23 billion U.S. expansion to meet rising demand for precision cancer treatments like Pluvicto and Lutathera. This marks the Swiss drugmaker’s fifth domestic RLT facility, underscoring the industry’s shift toward localized production amid geopolitical tariffs and supply chain pressures.
The Strategic Move Behind Novartis’ Texas Expansion
Novartis announced plans on February 25, 2026, to build a 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas. This move is part of the Swiss pharmaceutical giant’s broader $23 billion investment to expand its U.S. presence—a direct response to rising demand for targeted cancer treatments and mounting pressure from tariffs on foreign pharmaceutical imports.
The Texas site will join Novartis’ existing network of RLT facilities in New Jersey, Indiana, California, and a newly announced plant in Florida. Expected to become operational by 2028, the Denton facility will create specialized jobs in bioengineering, advanced manufacturing, and quality control, further entrenching the company in the burgeoning field of precision oncology.
Why Radioligand Therapy Is the Future of Cancer Care
Radioligand therapy represents a paradigm shift in cancer treatment. Unlike traditional chemotherapy, which attacks healthy cells alongside malignant ones, RLT delivers radiation directly to tumor cells via protein-targeting molecules. Novartis currently markets two FDA-approved RLT drugs: Pluvicto for prostate cancer and Lutathera for rare gastrointestinal tumors.
CEO Vas Narasimhan emphasized the strategic importance of the Texas site, stating, “The addition of our fifth RLT manufacturing site in the U.S. strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.” This expansion aligns with global trends in cancer care, where precision therapies are expected to grow at a 15% CAGR through 2030, according to industry analysts.
Geopolitical Pressures and the Push for Domestic Manufacturing
Novartis’ aggressive U.S. expansion is not occurring in a vacuum. The move is a direct response to the Trump administration’s 2025 tariffs on pharmaceutical imports, which escalated costs for drugmakers reliant on overseas production. By localizing manufacturing, Novartis joins competitors like Pfizer and Eli Lilly in insulating its supply chain from geopolitical volatility.
The Texas facility, slated for completion in 2028, will bolster domestic production of Pluvicto and Lutathera, reducing dependency on European imports. This shift mirrors broader industry trends, as drugmakers prioritize resilience over cost efficiency in an era of fragmented global trade.
Economic and Employment Impact in Texas
The Denton facility is projected to generate high-skilled jobs in bioengineering, advanced manufacturing, and regulated quality operations. While exact job numbers remain undisclosed, similar Novartis projects have created 200–300 positions per site, according to industry benchmarks.
Beyond direct employment, the plant will catalyze regional economic growth by fostering partnerships with local universities and research institutions. Texas, already a hub for medical innovation, stands to gain from Novartis’ long-term investment in RLT infrastructure.
What This Means for Cancer Patients
The expansion of RLT capacity directly impacts patient access to life-saving treatments. Pluvicto, approved in 2022, has shown a 38% reduction in mortality risk for late-stage prostate cancer patients, while Lutathera has doubled progression-free survival rates for gastrointestinal neuroendocrine tumors.
By scaling domestic production, Novartis aims to reduce waitlists and improve treatment continuity—critical for patients facing aggressive cancers. The Texas site will also accelerate clinical trials for new RLT candidates in development, such as the experimental drug 177Lu-PSMA-617, currently in Phase III.
Industry-Wide Shift Toward Targeted Therapies
Novartis’ bet on RLT reflects a broader transformation in oncology. The $23 billion U.S. investment mirrors similar expansions by AstraZeneca and Bristol Myers Squibb, which are also scaling radiopharmaceutical divisions. Experts predict that by 2030, one in four cancer patients may receive a targeted radiopharmaceutical treatment, up from just 5% today.
This shift is fueled by technological advancements in isotope production and FDA fast-track designations for novel RLT drugs. The Texas plant positions Novartis at the forefront of this wave, ensuring it remains competitive against rivals like Bayer and Johnson & Johnson, who are also investing in radiopharmaceuticals.
Stay ahead of the curve with onlytrustedinfo.com—where breaking news meets in-depth analysis. For the fastest, most authoritative updates on biotech innovation and healthcare policy, explore our full coverage.
